Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Image Source: Zacks Investment Research Linvoseltamab is an investigational BCMAxCD3 bispecific antibody ... these oncology drugs should be a great boost for REGN. Last month, Regeneron reported ...

which tested the antibody in 65 HoFH patients already being treated with statins, PCSK9 inhibitors and other drugs like ezetimibe. Adding in Regeneron’s antibody resulted in a 49% drop in ...

Regeneron beats quarterly estimates on eczema ... 2024 US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization ...

Biotech companies create drugs ... However, Regeneron actually meets the definition of a biotech instead. The company became practically a household name when its monoclonal antibody COVID-19 ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Regeneron's drug is the only therapy approved for CAPS ... and ACZ 885 (canakinumab), a fully humanized monoclonal antibody directed at IL-1β, from Novartis of Basel, Switzerland, currently ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer. Antibody-drug conjugates, or ADCs, have had a tremendous impact on the ...